Tandem Diabetes Care, Inc
Tandem Diabetes Care designs and commercializes insulin delivery systems and diabetes technology for people who require intensive insulin therapy. Its portfolio includes insulin pumps, mobile applications, and related software and supplies sold in the United States and in international markets through a mix of direct operations and distributors.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueReusable insulin pump hardware used for intensive insulin therapy.
Cartridges, infusion sets, and other recurring pump-related supplies.
Algorithms and software features such as Control-IQ+ that automate dosing.
Connected software tools that support monitoring, training, and data review.
Products
Reported · share of revenue- Supplies and Other54.3 %
- Pump45.7 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Tandem sells primarily to people living with insulin-dependent diabetes, especially individuals with type 1 diabetes who need intensive insulin therapy. The company also serves a smaller and expanding group of adults with type 2 diabetes who require intensive insulin treatment, along with the healthcare providers and diabetes educators who help initiate and train users on the devices.
Primary users of Tandem pumps and AID systems; they buy for intensive insulin management and convenience.
Adults eligible for pump therapy in selected markets; they buy for tighter glucose control and simpler dosing.
Prescribe devices, support onboarding, and influence product selection based on clinical outcomes.
Influence access through medical and pharmacy benefit coverage and reimbursement terms.
Strategy
Tandem’s strategy centers on expanding access to its insulin delivery systems through a broader reimbursement footprint, including both medical and pharmacy benefit channels. It is also extending its product platform with smaller form factors, extended-wear options, and more advanced automation to improve usability and strengthen its position in automated insulin delivery.
Coverage and benefit design directly affect patient adoption and recurring supply sales.
New form factors and software features help differentiate the offering and support retention.
Direct operations can improve customer support, reimbursement control, and market execution.
More automated insulin delivery can improve clinical outcomes and strengthen product relevance.
Geography
Q1/2026Tandem is headquartered in the United States and sells in more than 25 countries worldwide. The U.S. and Canada are served through direct sales and support, while many international markets have historically relied on distributors; the company has also begun expanding direct operations in selected European markets.
Share of the revenue the company reports by geography.
Risks
Tandem depends heavily on reimbursement access, distributor execution, and continued adoption of insulin pump therapy, so any disruption in coverage or channel performance can affect sales. The business also faces product, regulatory, supply chain, and competitive risks typical of medical device companies, including the possibility that new diabetes technologies or safety concerns reduce demand for its systems.
- Reimbursement and coverage riskImpact: HighLikelihood: Medium
Pump adoption depends on third-party payor coverage and benefit design, especially in the U.S.
Exposure: Medical and pharmacy benefit channels
- Distributor dependenceImpact: HighLikelihood: Medium
A small number of independent distributors fulfill orders in key markets and may also sell competing products.
Exposure - Supplier concentration and manufacturing disruptionImpact: HighLikelihood: Medium
The company relies on third-party suppliers for components and products, creating supply continuity risk.
Exposure - Competitive and technology obsolescenceImpact: MediumLikelihood: Medium
Alternative pumps, CGM-linked systems, or new diabetes therapies could reduce the appeal of Tandem's devices.
Exposure: Insulin delivery and automated insulin delivery market
- Regulatory and clinical execution riskImpact: MediumLikelihood: Medium
Clearances, trials, and human factors studies are required before commercialization of new products.
Exposure: U.S. FDA and foreign regulators
Accounting
Judgemental itemsDifferent product types and reimbursement pathways can affect timing of recognized revenue.
Impact: Quarterly comparability and mix between hardware and consumables
Device reliability and replacement expectations require management judgment.
Impact: Cost of sales and accrued liabilities
Demand forecasting and supplier arrangements can create excess or obsolete inventory risk.
Impact: Gross margin and inventory valuation
Technology acquisitions may require amortization and impairment testing.
Impact: Operating expenses and balance sheet carrying values
Financing instruments can create interest expense, covenant, and valuation complexity.
Impact: Interest expense, dilution, and liquidity presentation
Similar listed companies
Publicly listed companies with a comparable business focus.
Insulet Corporation
PODD · Surgical & Medical Instruments & Apparatus
Insulet Corporation develops, manufactures, and sells the Omnipod platform, a tubeless continuous insulin delivery system for people with insulin-dependent diabetes.
Modular Medical, Inc.
MODD · Surgical & Medical Instruments & Apparatus
Senseonics Holdings, Inc.
SENS · Industrial Instruments For Measurement, Display, and Control
Glucotrack, Inc.
GCTK · Surgical & Medical Instruments & Apparatus
DexCom, Inc
DXCM · Surgical & Medical Instruments & Apparatus
DexCom is a U.S.
Medtronic plc
MDT · Electromedical & Electrotherapeutic Apparatus
Medtronic plc designs, manufactures, and sells medical technologies used to diagnose, treat, and manage chronic and acute conditions across the body.
Last updated: 24/09/2026